ATE456371T1 - Verwendung von o-atp für die behandlung von angiogenese-bezogenen krankheiten - Google Patents

Verwendung von o-atp für die behandlung von angiogenese-bezogenen krankheiten

Info

Publication number
ATE456371T1
ATE456371T1 AT05707370T AT05707370T ATE456371T1 AT E456371 T1 ATE456371 T1 AT E456371T1 AT 05707370 T AT05707370 T AT 05707370T AT 05707370 T AT05707370 T AT 05707370T AT E456371 T1 ATE456371 T1 AT E456371T1
Authority
AT
Austria
Prior art keywords
angiogenesis
atp
treatment
related diseases
diseases
Prior art date
Application number
AT05707370T
Other languages
English (en)
Inventor
Maria Elena Ferrero
Original Assignee
Medestea Int Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medestea Int Spa filed Critical Medestea Int Spa
Application granted granted Critical
Publication of ATE456371T1 publication Critical patent/ATE456371T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Toilet Supplies (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Compositions Of Oxide Ceramics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT05707370T 2004-02-17 2005-02-14 Verwendung von o-atp für die behandlung von angiogenese-bezogenen krankheiten ATE456371T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000255A ITMI20040255A1 (it) 2004-02-17 2004-02-17 Sostanze ad attivita' antiangiogenica
PCT/EP2005/001458 WO2005077383A1 (en) 2004-02-17 2005-02-14 The use of o-atp for the treatment of diseases involving angiogenesis

Publications (1)

Publication Number Publication Date
ATE456371T1 true ATE456371T1 (de) 2010-02-15

Family

ID=34856914

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05707370T ATE456371T1 (de) 2004-02-17 2005-02-14 Verwendung von o-atp für die behandlung von angiogenese-bezogenen krankheiten

Country Status (16)

Country Link
US (1) US20070099864A1 (de)
EP (1) EP1732574B1 (de)
JP (1) JP2007522177A (de)
KR (1) KR20070007786A (de)
CN (1) CN1917887A (de)
AT (1) ATE456371T1 (de)
AU (1) AU2005211924A1 (de)
BR (1) BRPI0507738A (de)
CA (1) CA2556601A1 (de)
DE (1) DE602005019142D1 (de)
ES (1) ES2336011T3 (de)
IT (1) ITMI20040255A1 (de)
NO (1) NO20063686L (de)
PL (1) PL1732574T3 (de)
RU (1) RU2359679C2 (de)
WO (1) WO2005077383A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2417758C1 (ru) * 2009-10-21 2011-05-10 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Федерального агентства по высокотехнологичной медицинской помощи" Способ оценки эффективности противоопухолевой терапии при нейробластомах у детей
FR3041260B1 (fr) * 2015-09-21 2020-10-02 Hopitaux Paris Assist Publique Utilisation d'un tripeptide cyclique pour stimuler l'activite mitochondriale de cellules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324731A (en) * 1989-02-14 1994-06-28 Amira, Inc. Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated
IT1318667B1 (it) * 2000-08-04 2003-08-27 Univ Degli Studi Milano Medicamento antinfiammatorio.
WO2003042190A1 (en) * 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
PA8557501A1 (es) * 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
US20050053612A1 (en) * 2003-08-20 2005-03-10 Granstein Richard D. Nucleotide regulation of immune responses

Also Published As

Publication number Publication date
EP1732574A1 (de) 2006-12-20
EP1732574B1 (de) 2010-01-27
US20070099864A1 (en) 2007-05-03
CA2556601A1 (en) 2005-08-25
ITMI20040255A1 (it) 2004-05-17
KR20070007786A (ko) 2007-01-16
BRPI0507738A (pt) 2007-07-10
JP2007522177A (ja) 2007-08-09
NO20063686L (no) 2006-08-16
ES2336011T3 (es) 2010-04-07
PL1732574T3 (pl) 2010-07-30
WO2005077383A1 (en) 2005-08-25
RU2359679C2 (ru) 2009-06-27
DE602005019142D1 (de) 2010-03-18
AU2005211924A1 (en) 2005-08-25
CN1917887A (zh) 2007-02-21
RU2006129748A (ru) 2008-02-27

Similar Documents

Publication Publication Date Title
NL300933I2 (nl) Letermovir
ATE374196T1 (de) Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen
DE60329123D1 (de) Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
DE60124576D1 (de) Verbindungen verwendbar für die behandlung von entzündungskrankheiten
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
ATE402165T1 (de) Piperazin derivate und ihre verwendung für die behandlung von neurologischen und psychiatrischen krankheiten.
DE60239558D1 (de) Kombinationen für die behandlung von immun-entzündlichen erkrankungen
ATE551340T1 (de) Azabicyclisch- substituierte annelierte heteroaryl-verbinungen für die behandlung von krankheiten
DE60325498D1 (de) 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen
DE602004012725D1 (de) Quinazolin-derivate für die behandling von krebs
ATE470723T1 (de) Genexpressionsmarker für die prognose von brustkrebs
EA200500520A1 (ru) Пуриновые соединения и их применение в качестве лигандов каннабиноидных рецепторов
DE60204951D1 (de) Ccr5 antagonisten verwendbar für die behandlung von aids
ATE422498T1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
ATE489361T1 (de) Derivate von alpha-phenylthiocarbon- und alpha- phenyloxycarbonsäuren, die für die behandlung von auf die aktivierung von ppar alpha ansprechende krankheiten geeignet sind
SE0302304D0 (sv) Novel compounds
ATE333872T1 (de) Zusammensetzng auf diclofenac-basis für die topische behandlung von erkrankungen des oropharynx
ATE456371T1 (de) Verwendung von o-atp für die behandlung von angiogenese-bezogenen krankheiten
NO20032406D0 (no) Anvendelse av 1-fenyl-3-dimetylaminopropanforbindelser for behandling av urininkontinens
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
ATE345135T1 (de) Tropan-derivate mit dopamin-wiederaufnahme-hemmer-wirkung für die behandlung von ischämischen erkrankungen
ATE277924T1 (de) Aryl-8-azabicyclo(3.2.1)octanes für die behandlung von depression
DE60133596D1 (de) S-Methyl-Dihydro-Ziprasidone für die Behandlung von Schizophrenie
EP1553911A4 (de) 2-heterosubstituierte 3-aryl-4-h-1-benzopyran-4-one als neue therapeutika bei brustkrebs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties